The omicron-targeted vaccine from Pfizer Inc. and a hybrid injection that fights both the parent strain and ommicron elicited strong immune responses in a study that could pave the way for the next generation of COVID-19 vaccines.
Visit our dedicated page for more news about the coronavirus.
Pfizer and its vaccine partner, Germany’s BioNTech SE, said on Saturday that both new vaccine candidates had a safety and tolerability profile similar to the original injection.
The companies said the data will be discussed with regulators with the aim of quickly introducing a more customized booster shot to address current and future variants.
Data from the late phase of the study showed that a booster dose of both omicron-modified vaccine candidates elicited a “significantly higher” immune response against omicron subvariant BA.1 compared to the current COVID-19 vaccine.
For the latest headlines, follow our Google News channel online or via the app.
Some ommicron subvariants escaping antibodies from Sinopharm recording: Chinese study
Nasal swabs still best method to test for COVID-19: Study
COVID-19 vaccine campaign for the world’s poorest forces manufacturers to delay delivery